Eurobio Scientific Société anonyme Past Earnings Performance
Past criteria checks 2/6
Eurobio Scientific Société anonyme's earnings have been declining at an average annual rate of -10.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8.7% per year. Eurobio Scientific Société anonyme's return on equity is 3.7%, and it has net margins of 4.6%.
Key information
-10.1%
Earnings growth rate
-11.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 8.7% |
| Return on equity | 3.7% |
| Net Margin | 4.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Eurobio Scientific Société anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 145 | 7 | 40 | 6 |
| 31 Mar 24 | 138 | 6 | 37 | 6 |
| 31 Dec 23 | 131 | 5 | 34 | 6 |
| 30 Sep 23 | 129 | 6 | 31 | 6 |
| 30 Jun 23 | 128 | 8 | 29 | 5 |
| 31 Mar 23 | 140 | 16 | 30 | 4 |
| 31 Dec 22 | 153 | 25 | 31 | 3 |
| 30 Sep 22 | 163 | 36 | 28 | 3 |
| 30 Jun 22 | 174 | 47 | 26 | 1 |
| 31 Mar 22 | 180 | 54 | 25 | 1 |
| 31 Dec 21 | 185 | 61 | 24 | 0 |
| 30 Sep 21 | 204 | 71 | 25 | -1 |
| 30 Jun 21 | 223 | 81 | 27 | 0 |
| 31 Mar 21 | 206 | 77 | 26 | 0 |
| 31 Dec 20 | 189 | 73 | 23 | 0 |
| 30 Sep 20 | 141 | 51 | 20 | 0 |
| 30 Jun 20 | 92 | 28 | 17 | 0 |
| 31 Mar 20 | 76 | 16 | 16 | 0 |
| 31 Dec 19 | 59 | 3 | 15 | 0 |
| 30 Sep 19 | 58 | 1 | 16 | 0 |
| 30 Jun 19 | 56 | -2 | 17 | 0 |
| 31 Mar 19 | 53 | -2 | 16 | 0 |
| 31 Dec 18 | 51 | -3 | 16 | 0 |
| 30 Sep 18 | 50 | -4 | 17 | 0 |
| 30 Jun 18 | 48 | -6 | 17 | 0 |
| 31 Mar 18 | 46 | -8 | 17 | 0 |
| 31 Dec 17 | 43 | -10 | 17 | 0 |
| 30 Sep 17 | 38 | -9 | 15 | 0 |
| 30 Jun 17 | 32 | -9 | 13 | 0 |
| 31 Mar 17 | 30 | -8 | 13 | 0 |
| 31 Dec 16 | 28 | -8 | 13 | 0 |
| 30 Sep 16 | 28 | -8 | 13 | 0 |
| 30 Jun 16 | 29 | -8 | 13 | 0 |
| 31 Mar 16 | 29 | -7 | 13 | 0 |
| 31 Dec 15 | 30 | -6 | 13 | 0 |
| 30 Sep 15 | 30 | -6 | 14 | 0 |
| 30 Jun 15 | 31 | -6 | 15 | 0 |
| 31 Mar 15 | 31 | -6 | 14 | 0 |
| 31 Dec 14 | 31 | -5 | 14 | 0 |
| 30 Sep 14 | 31 | -5 | 14 | 0 |
| 30 Jun 14 | 31 | -5 | 14 | 0 |
| 31 Mar 14 | 31 | -6 | 14 | 0 |
| 31 Dec 13 | 31 | -6 | 14 | 0 |
Quality Earnings: E8TN has high quality earnings.
Growing Profit Margin: E8TN's current net profit margins (4.6%) are lower than last year (6.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: E8TN has become profitable over the past 5 years, growing earnings by -10.1% per year.
Accelerating Growth: E8TN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: E8TN had negative earnings growth (-16%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).
Return on Equity
High ROE: E8TN's Return on Equity (3.7%) is considered low.